Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy
To compare the effects of brimonidine 0.2% and apraclonidine 1% on intraocular pressure (IOP) and pupil size in patients undergoing laser peripheral iridotomy (LPI). Forty patients (40 eyes) with occludable angle or angle-closure glaucoma requiring LPI were recruited. Patients were randomized to rec...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of ophthalmology 2005-03, Vol.49 (2), p.89-92 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 92 |
|---|---|
| container_issue | 2 |
| container_start_page | 89 |
| container_title | Japanese journal of ophthalmology |
| container_volume | 49 |
| creator | Yuen, Nancy S Y Cheung, Peggy Hui, Sui Ping |
| description | To compare the effects of brimonidine 0.2% and apraclonidine 1% on intraocular pressure (IOP) and pupil size in patients undergoing laser peripheral iridotomy (LPI).
Forty patients (40 eyes) with occludable angle or angle-closure glaucoma requiring LPI were recruited. Patients were randomized to receive either brimonidine 0.2% or apraclonidine 1% before and after LPI. The IOPs were measured at 1, 2 and 3 h after LPI, and pupil size was measured before and at 45 min after eyedrop instillation. Both parameters were analyzed using the t test.
There were 20 patients in each group. The baseline IOP was 17.1 +/- 3.2 mmHg for the brimonidine group and 16.7 +/- 2.8 mmHg for the apraclonidine group (P = 0.67) (t test). The mean IOP 3 h after laser treatment was 18.2 +/- 7.8 mmHg for the brimonidine group and 15.7 +/- 5.6 mmHg for the apraclonidine group (P = 0.25) (t test). There was no statistically significant difference between the two groups in the mean IOP changes at 1, 2, or 3 h after LPI. The mean change in pupil size after brimonidine was -0.33 +/- 0.37 mm and after apraclonidine was +0.90 +/- 0.87 mm. The difference was significant (P < 0.001).
Brimonidine 0.2% was found to have an efficacy comparable to that of apraclonidine 1.0% in preventing post LPI IOP spikes. Apraclonidine 1.0% tends to have a pupil dilating effect while brimonidine 0.2% tends to constrict the pupil. |
| doi_str_mv | 10.1007/s10384-004-0149-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67757369</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>932353811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-1bc4041e792fecee529c6bc4d9a410b522e4b3d0bfab20e978b9c52a73e852be3</originalsourceid><addsrcrecordid>eNpdkd9qFTEQxoMo9rT6AN5IEOrdHjPJZv9cyqG1QqE3eh2S7KxNySZrslvpA_U9zXqOCF6EwMzvG76Zj5B3wPbAWPspAxNdXTFWHtR91b8gO2hAVJzXzUuyY4xDJUHKM3Ke8wMrIBf8NTkD2Ymu5WJHng9xmnVy4Qc1yU0xuMEFpGzPL-kSqZ6Ttv5vFfbskrpAl3ukc8JHDIuLgcaxFJeko129Tlsn5zUhRY-P-g-hw7CJXGmus_OFeqI4jmiXTMfoffy1GfA6YyEwufkek_bUJTfEJU5Pb8irUfuMb0__Bfl-ffXtcFPd3n35evh8W9kamqUCY2tWA7Y9L7MRJe9tU2pDr2tgRnKOtREDM6M2nGHfdqa3kutWYCe5QXFBPh7nzin-XDEvanLZYjEcMK5ZNW0rW9H0BfzwH_gQ1xSKN8UFACsH3iA4QjbFnBOOai4nLrsrYGoLUB0DVCUXtQWoNs370-DVTDj8U5wSE78BTMiZtA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>231101589</pqid></control><display><type>article</type><title>Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Yuen, Nancy S Y ; Cheung, Peggy ; Hui, Sui Ping</creator><creatorcontrib>Yuen, Nancy S Y ; Cheung, Peggy ; Hui, Sui Ping</creatorcontrib><description>To compare the effects of brimonidine 0.2% and apraclonidine 1% on intraocular pressure (IOP) and pupil size in patients undergoing laser peripheral iridotomy (LPI).
Forty patients (40 eyes) with occludable angle or angle-closure glaucoma requiring LPI were recruited. Patients were randomized to receive either brimonidine 0.2% or apraclonidine 1% before and after LPI. The IOPs were measured at 1, 2 and 3 h after LPI, and pupil size was measured before and at 45 min after eyedrop instillation. Both parameters were analyzed using the t test.
There were 20 patients in each group. The baseline IOP was 17.1 +/- 3.2 mmHg for the brimonidine group and 16.7 +/- 2.8 mmHg for the apraclonidine group (P = 0.67) (t test). The mean IOP 3 h after laser treatment was 18.2 +/- 7.8 mmHg for the brimonidine group and 15.7 +/- 5.6 mmHg for the apraclonidine group (P = 0.25) (t test). There was no statistically significant difference between the two groups in the mean IOP changes at 1, 2, or 3 h after LPI. The mean change in pupil size after brimonidine was -0.33 +/- 0.37 mm and after apraclonidine was +0.90 +/- 0.87 mm. The difference was significant (P < 0.001).
Brimonidine 0.2% was found to have an efficacy comparable to that of apraclonidine 1.0% in preventing post LPI IOP spikes. Apraclonidine 1.0% tends to have a pupil dilating effect while brimonidine 0.2% tends to constrict the pupil.</description><identifier>ISSN: 0021-5155</identifier><identifier>EISSN: 1613-2246</identifier><identifier>DOI: 10.1007/s10384-004-0149-9</identifier><identifier>PMID: 15838723</identifier><language>eng</language><publisher>Japan: Springer Nature B.V</publisher><subject><![CDATA[Adrenergic alpha-Agonists - administration & dosage ; Adrenergic alpha-Agonists - pharmacology ; Aged ; Brimonidine Tartrate ; Clonidine - administration & dosage ; Clonidine - analogs & derivatives ; Clonidine - pharmacology ; Double-Blind Method ; Female ; Glaucoma, Angle-Closure - surgery ; Humans ; Intraocular Pressure - drug effects ; Iridectomy ; Laser Therapy ; Male ; Ocular Hypertension - prevention & control ; Ophthalmic Solutions - administration & dosage ; Ophthalmic Solutions - pharmacology ; Postoperative Complications - prevention & control ; Prospective Studies ; Pupil - drug effects ; Quinoxalines - administration & dosage ; Quinoxalines - pharmacology]]></subject><ispartof>Japanese journal of ophthalmology, 2005-03, Vol.49 (2), p.89-92</ispartof><rights>Japanese Ophthalmological Society 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-1bc4041e792fecee529c6bc4d9a410b522e4b3d0bfab20e978b9c52a73e852be3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15838723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuen, Nancy S Y</creatorcontrib><creatorcontrib>Cheung, Peggy</creatorcontrib><creatorcontrib>Hui, Sui Ping</creatorcontrib><title>Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy</title><title>Japanese journal of ophthalmology</title><addtitle>Jpn J Ophthalmol</addtitle><description>To compare the effects of brimonidine 0.2% and apraclonidine 1% on intraocular pressure (IOP) and pupil size in patients undergoing laser peripheral iridotomy (LPI).
Forty patients (40 eyes) with occludable angle or angle-closure glaucoma requiring LPI were recruited. Patients were randomized to receive either brimonidine 0.2% or apraclonidine 1% before and after LPI. The IOPs were measured at 1, 2 and 3 h after LPI, and pupil size was measured before and at 45 min after eyedrop instillation. Both parameters were analyzed using the t test.
There were 20 patients in each group. The baseline IOP was 17.1 +/- 3.2 mmHg for the brimonidine group and 16.7 +/- 2.8 mmHg for the apraclonidine group (P = 0.67) (t test). The mean IOP 3 h after laser treatment was 18.2 +/- 7.8 mmHg for the brimonidine group and 15.7 +/- 5.6 mmHg for the apraclonidine group (P = 0.25) (t test). There was no statistically significant difference between the two groups in the mean IOP changes at 1, 2, or 3 h after LPI. The mean change in pupil size after brimonidine was -0.33 +/- 0.37 mm and after apraclonidine was +0.90 +/- 0.87 mm. The difference was significant (P < 0.001).
Brimonidine 0.2% was found to have an efficacy comparable to that of apraclonidine 1.0% in preventing post LPI IOP spikes. Apraclonidine 1.0% tends to have a pupil dilating effect while brimonidine 0.2% tends to constrict the pupil.</description><subject>Adrenergic alpha-Agonists - administration & dosage</subject><subject>Adrenergic alpha-Agonists - pharmacology</subject><subject>Aged</subject><subject>Brimonidine Tartrate</subject><subject>Clonidine - administration & dosage</subject><subject>Clonidine - analogs & derivatives</subject><subject>Clonidine - pharmacology</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Glaucoma, Angle-Closure - surgery</subject><subject>Humans</subject><subject>Intraocular Pressure - drug effects</subject><subject>Iridectomy</subject><subject>Laser Therapy</subject><subject>Male</subject><subject>Ocular Hypertension - prevention & control</subject><subject>Ophthalmic Solutions - administration & dosage</subject><subject>Ophthalmic Solutions - pharmacology</subject><subject>Postoperative Complications - prevention & control</subject><subject>Prospective Studies</subject><subject>Pupil - drug effects</subject><subject>Quinoxalines - administration & dosage</subject><subject>Quinoxalines - pharmacology</subject><issn>0021-5155</issn><issn>1613-2246</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkd9qFTEQxoMo9rT6AN5IEOrdHjPJZv9cyqG1QqE3eh2S7KxNySZrslvpA_U9zXqOCF6EwMzvG76Zj5B3wPbAWPspAxNdXTFWHtR91b8gO2hAVJzXzUuyY4xDJUHKM3Ke8wMrIBf8NTkD2Ymu5WJHng9xmnVy4Qc1yU0xuMEFpGzPL-kSqZ6Ttv5vFfbskrpAl3ukc8JHDIuLgcaxFJeko129Tlsn5zUhRY-P-g-hw7CJXGmus_OFeqI4jmiXTMfoffy1GfA6YyEwufkek_bUJTfEJU5Pb8irUfuMb0__Bfl-ffXtcFPd3n35evh8W9kamqUCY2tWA7Y9L7MRJe9tU2pDr2tgRnKOtREDM6M2nGHfdqa3kutWYCe5QXFBPh7nzin-XDEvanLZYjEcMK5ZNW0rW9H0BfzwH_gQ1xSKN8UFACsH3iA4QjbFnBOOai4nLrsrYGoLUB0DVCUXtQWoNs370-DVTDj8U5wSE78BTMiZtA</recordid><startdate>20050301</startdate><enddate>20050301</enddate><creator>Yuen, Nancy S Y</creator><creator>Cheung, Peggy</creator><creator>Hui, Sui Ping</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20050301</creationdate><title>Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy</title><author>Yuen, Nancy S Y ; Cheung, Peggy ; Hui, Sui Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-1bc4041e792fecee529c6bc4d9a410b522e4b3d0bfab20e978b9c52a73e852be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adrenergic alpha-Agonists - administration & dosage</topic><topic>Adrenergic alpha-Agonists - pharmacology</topic><topic>Aged</topic><topic>Brimonidine Tartrate</topic><topic>Clonidine - administration & dosage</topic><topic>Clonidine - analogs & derivatives</topic><topic>Clonidine - pharmacology</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Glaucoma, Angle-Closure - surgery</topic><topic>Humans</topic><topic>Intraocular Pressure - drug effects</topic><topic>Iridectomy</topic><topic>Laser Therapy</topic><topic>Male</topic><topic>Ocular Hypertension - prevention & control</topic><topic>Ophthalmic Solutions - administration & dosage</topic><topic>Ophthalmic Solutions - pharmacology</topic><topic>Postoperative Complications - prevention & control</topic><topic>Prospective Studies</topic><topic>Pupil - drug effects</topic><topic>Quinoxalines - administration & dosage</topic><topic>Quinoxalines - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuen, Nancy S Y</creatorcontrib><creatorcontrib>Cheung, Peggy</creatorcontrib><creatorcontrib>Hui, Sui Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuen, Nancy S Y</au><au>Cheung, Peggy</au><au>Hui, Sui Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy</atitle><jtitle>Japanese journal of ophthalmology</jtitle><addtitle>Jpn J Ophthalmol</addtitle><date>2005-03-01</date><risdate>2005</risdate><volume>49</volume><issue>2</issue><spage>89</spage><epage>92</epage><pages>89-92</pages><issn>0021-5155</issn><eissn>1613-2246</eissn><abstract>To compare the effects of brimonidine 0.2% and apraclonidine 1% on intraocular pressure (IOP) and pupil size in patients undergoing laser peripheral iridotomy (LPI).
Forty patients (40 eyes) with occludable angle or angle-closure glaucoma requiring LPI were recruited. Patients were randomized to receive either brimonidine 0.2% or apraclonidine 1% before and after LPI. The IOPs were measured at 1, 2 and 3 h after LPI, and pupil size was measured before and at 45 min after eyedrop instillation. Both parameters were analyzed using the t test.
There were 20 patients in each group. The baseline IOP was 17.1 +/- 3.2 mmHg for the brimonidine group and 16.7 +/- 2.8 mmHg for the apraclonidine group (P = 0.67) (t test). The mean IOP 3 h after laser treatment was 18.2 +/- 7.8 mmHg for the brimonidine group and 15.7 +/- 5.6 mmHg for the apraclonidine group (P = 0.25) (t test). There was no statistically significant difference between the two groups in the mean IOP changes at 1, 2, or 3 h after LPI. The mean change in pupil size after brimonidine was -0.33 +/- 0.37 mm and after apraclonidine was +0.90 +/- 0.87 mm. The difference was significant (P < 0.001).
Brimonidine 0.2% was found to have an efficacy comparable to that of apraclonidine 1.0% in preventing post LPI IOP spikes. Apraclonidine 1.0% tends to have a pupil dilating effect while brimonidine 0.2% tends to constrict the pupil.</abstract><cop>Japan</cop><pub>Springer Nature B.V</pub><pmid>15838723</pmid><doi>10.1007/s10384-004-0149-9</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-5155 |
| ispartof | Japanese journal of ophthalmology, 2005-03, Vol.49 (2), p.89-92 |
| issn | 0021-5155 1613-2246 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67757369 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adrenergic alpha-Agonists - administration & dosage Adrenergic alpha-Agonists - pharmacology Aged Brimonidine Tartrate Clonidine - administration & dosage Clonidine - analogs & derivatives Clonidine - pharmacology Double-Blind Method Female Glaucoma, Angle-Closure - surgery Humans Intraocular Pressure - drug effects Iridectomy Laser Therapy Male Ocular Hypertension - prevention & control Ophthalmic Solutions - administration & dosage Ophthalmic Solutions - pharmacology Postoperative Complications - prevention & control Prospective Studies Pupil - drug effects Quinoxalines - administration & dosage Quinoxalines - pharmacology |
| title | Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T09%3A21%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparing%20brimonidine%200.2%25%20to%20apraclonidine%201.0%25%20in%20the%20prevention%20of%20intraocular%20pressure%20elevation%20and%20their%20pupillary%20effects%20following%20laser%20peripheral%20iridotomy&rft.jtitle=Japanese%20journal%20of%20ophthalmology&rft.au=Yuen,%20Nancy%20S%20Y&rft.date=2005-03-01&rft.volume=49&rft.issue=2&rft.spage=89&rft.epage=92&rft.pages=89-92&rft.issn=0021-5155&rft.eissn=1613-2246&rft_id=info:doi/10.1007/s10384-004-0149-9&rft_dat=%3Cproquest_cross%3E932353811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=231101589&rft_id=info:pmid/15838723&rfr_iscdi=true |